Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC Versus Chemotherapy in HER2-low Advanced or Metastatic Breast Cancer
CTR20200646Phase 3Completed
- Sponsor
- RemeGen
- Start
- May 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin in breast cancer, sponsored by RemeGen. Started May 2020; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20200646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200646.